Dr. Prem Kumar Mony

Professor, Division of Epidemiology & Population Health, St. John’s Medical College and Research Institute, Bangalore

MBBS, MD, MSc (Clinical Epidemiology)

ORCID: 0000-0002-1399-0520

Linkedin: https://www.linkedin.com/in/prem-mony-99402223/

Skills and Expertise

Dr. Prem Kumar Mony is a Professor in the Division of Epidemiology and Population Health at St. John’s Medical College and Research Institute, Bangalore. He is a clinical epidemiologist with over two decades of experience in non-communicable disease research, cardiovascular epidemiology, and global health. He is a principal investigator for the India component of the landmark Prospective Urban Rural Epidemiology (PURE) study — one of the largest multinational cohort studies spanning 21 countries across five continents — which has generated landmark evidence on cardiovascular risk factors, diet, medicine availability, and mortality in diverse global populations. His research interests span epidemiology of NCDs, maternal and neonatal health, wearable health technology, and air pollution. He has contributed to over 100 peer-reviewed publications in leading international journals.

Publications

1. Yusuf S, Joseph P, Rangarajan S, Mony P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Sep 3;395(10226):795-808. doi: [10.1016/S0140-6736(19)32008-2](https://doi.org/10.1016/S0140-6736(19)32008-2). PubMed PMID: 31492503. 2. Dehghan M, Mente A, Rangarajan S, Mony P, et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2018 Sep 11;392(10161):2288-2297. doi: [10.1016/S0140-6736(18)31812-9](https://doi.org/10.1016/S0140-6736(18)31812-9). PubMed PMID: 30217460. 3. Khatib R, McKee M, Shannon H, Mony P, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016 Jan 9;387(10013):61-69. doi: [10.1016/S0140-6736(15)00469-9](https://doi.org/10.1016/S0140-6736(15)00469-9). PubMed PMID: 26498706. 4. Lopez-Jaramillo P, Gomez-Arbelaez D, Mony PK, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023 Jan;4(1):e23-e33. doi: [10.1016/S2666-7568(22)00247-1](https://doi.org/10.1016/S2666-7568(22)00247-1). PubMed PMID: 36521498. 5. Joseph P, Avezum A, Mony PK, et al. Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study. J Am Coll Cardiol. 2025 Feb 11;85(5):436-447. doi: [10.1016/j.jacc.2024.10.121](https://doi.org/10.1016/j.jacc.2024.10.121). PubMed PMID: 39909677.